The earnings miss is largely discounted by the market given the pre-revenue stage. Focus is on the upcoming OPUS-1 topline readout in Q4 2026, which is the key catalyst. Monitor stock price volatility around Phase 3 data expectations and any regulatory updates.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $51.48entry
- T+1 · 6mo ago +2.97%α +2.14% · $53.01
- T+5 · 6mo ago +5.38%α +3.88% · $54.25
- T+20 · 6mo ago −8.84%α −11.97% · $46.93
- T+60 · 4mo ago +3.98%α +0.15% · $53.53
Price Chart
How similar events traded
Executive Summary
Vaxcyte reported Q1 2026 net loss of $320.6M (-$2.30 per share), significantly worse than the consensus estimate of -$1.86 and more than double the prior year's loss of $140.7M. R&D expenses surged to $312.8M as Phase 3 trials enrolled fully. The earnings miss is overshadowed by pipeline progress, with all three OPUS Phase 3 trials now fully enrolled and OPUS-1 topline data expected in Q4 2026.
Key Financial Metrics
Key Facts
- Net loss per share Q1 2026: -$2.30 vs consensus -$1.86 (23.7% miss)
- Net loss widened to $320.6M from $140.7M YoY
- R&D expenses increased to $312.8M from $148.1M YoY
- Cash, cash equivalents and investments: $2.74B as of March 31, 2026 (up from $2.44B in December 2025, including $601.8M net from Feb equity offering)
- Enrollment completed for all three OPUS Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) with 6,191 adults dosed
- VAX-31 Phase 1/2 adult data published in The Lancet Infectious Diseases
- VAX-31 infant Phase 2 study fully enrolled; infant data expected by end of first half 2027
Financial Impact
EPS miss of $0.44 per share vs consensus, representing a 23.7% negative surprise
Risk Factors
- OPUS-1 Phase 3 data may fail to meet noninferiority or superiority endpoints
- Cash burn rate is accelerating; additional equity dilutive financing may be needed before commercialization
- Regulatory or manufacturing delays could push BLA submission beyond current timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001649094-26-000015 |
| Document: pcvx-20260506.htm | 0001649094-26-000015 |
| Document: 0001649094-26-000015-index-headers.html | 0001649094-26-000015 |
| Document: 0001649094-26-000015-index.html | 0001649094-26-000015 |
| Document: 0001649094-26-000015.txt | 0001649094-26-000015 |
| 8-K Data (Synthetic) | 0001649094-26-000015 |
Track record
29 reports on PCVX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers